Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
Ovulation · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation compared with an insulin‐sensitising agent (metformin) (very low certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Live birth · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes live birth compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
Clinical pregnancy · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ovulation rate · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes ovulation rate compared with an ovulation induction agent (clomiphene) (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
Myo‐inositol showed no clear difference in adverse event ‐ multiple pregnancy compared with placebo, no/standard treatment (low certainty).
1 finding from 1 review
Clinical pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes clinical pregnancy compared with placebo, no/standard treatment (very low certainty).
1 finding from 1 review
Ovulation · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth · subfertile women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ Miscarriage · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ miscarriage compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · subfertile women with polycystic ovary syndrome
It is very uncertain whether myo‐inositol changes adverse event ‐ multiple pregnancy compared with antioxidant (melatonin) (very low certainty).
1 finding from 1 review